# Mice Model - Global Strategic Business Report 2026: Capitalize on a $3.4 Billion Market by 2032 as Charles River, LabCorp, Taconic Biosciences and The Jackson Laboratory Accelerate CRISPR

- Published: 2026-11-16
- Author: [BiotechNews.io](https://biotechnews.io/author/biotechnews-io.md)
- Topics: [News](https://biotechnews.io/news.md)
- Source: https://biotechnews.io/news/mice-model-global-strategic-business-report-2026-capitalize-on-a-3-4-billion-market-by-203/
- Publication: Biotech News
- Publisher: Connectively (Terkel, Inc.)
- Editorial policy: https://biotechnews.io/editorial-policy/

*Target CRISPR-enabled models, personalized medicine, and pharma-academic partnerships to accelerate drug development and unlock new revenue opportunities.*

Dublin, Nov. 16, 2026 [(GLOBE NEWSWIRE)](https://www.globenewswire.com) -- <a href="https://www.researchandmarkets.com/reports/4805185/mice-model-global-strategic-business-report-2026?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=h66mjd&amp;utm_campaign=2404484+-+Mice+Model+-+Global+Strategic+Business+Report+2026%3a+Capitalize+on+a+%243.4+Billion+Market+by+2032+as+Charles+River%2c+LabCorp%2c+Taconic+Biosciences+and+The+Jackson+Laboratory+Accelerate+CRISPR&amp;utm_exec=clshmsai" rel="nofollow">"Mice Model - Global Strategic Business Report 2026"</a> has been added to **ResearchAndMarkets.com's** offering.

**Global Mice Model Market to Reach US$3.4 Billion by 2032 as Genome Editing and Personalized Medicine Accelerate Demand**

The global mice model market was valued at US$1.8 billion in 2025 and is projected to reach US$3.4 billion by 2032, expanding at a compound annual growth rate (CAGR) of 9.3%. Market growth is being supported by advances in genetic engineering, rising pharmaceutical and biotechnology research and development expenditure, increasing demand for personalized medicine, and the continued need for sophisticated preclinical models.

**Genetic Engineering Strengthens Biomedical Research Applications**

Genome editing technologies are transforming the development and use of mice models across drug discovery, disease research, and precision medicine. CRISPR/Cas9 and other genetic modification techniques enable researchers to produce highly targeted models that replicate specific mutations, pathways, and disease mechanisms. These capabilities support more focused target validation, efficacy studies, safety assessments, and therapeutic development programs.

Continued refinement of gene-editing methods is improving research efficiency and expanding the application of mice models in oncology, immunology, metabolic disease, cardiovascular research, and neurological disorders. The resulting models can help pharmaceutical companies, biotechnology organizations, academic institutions, and contract research organizations investigate complex genetic interactions and advance potential treatments through preclinical development.

**Market Challenges Include Translational Accuracy, Cost, and Ethics**

Despite their extensive role in biomedical research, mice models may not always reproduce human disease progression or treatment response with complete accuracy. Differences in immune function, metabolism, physiology, and genetic expression can create translational limitations. Researchers must therefore select and validate models carefully, often combining animal studies with complementary analytical and experimental methods.

Cost is another significant consideration. Developing, breeding, maintaining, and housing genetically engineered mice can require substantial infrastructure and specialist expertise, particularly for large-scale or high-throughput studies. Animal welfare requirements and evolving regulatory standards also influence research protocols, facility operations, and investment decisions across the mice model market.

**Key Mice Model Market Growth Drivers**

Growth is being driven by the increasing prevalence of chronic and genetically linked diseases, sustained investment in pharmaceutical research and development, and the expansion of targeted and personalized therapies. Collaboration among biotechnology companies, pharmaceutical manufacturers, academic research institutes, CROs, and CDMOs is also accelerating model development and widening commercial adoption.

The CRISPR/Cas9 technology segment is forecast to reach US$1.1 billion by 2032, advancing at a CAGR of 11.4%. The microinjections technology segment is projected to grow at a CAGR of 8.5% over the analysis period. These technologies are expected to remain central to the creation of specialized models for drug discovery and disease research.

**Regional Market Outlook**

The United States mice model market was valued at US$483.5 million in 2025, reflecting the country's established pharmaceutical, biotechnology, and academic research infrastructure. China is forecast to expand at a CAGR of 14.5% and reach US$817.8 million by 2032, supported by growing life sciences investment, research capacity, and domestic biopharmaceutical activity.

The report also evaluates market developments across Canada, Japan, Germany, France, Italy, the United Kingdom, Spain, Russia, Australia, India, South Korea, Latin America, the Middle East, and Africa. Regional analysis highlights differences in research funding, regulatory environments, biotechnology investment, outsourcing activity, and adoption of advanced genome-editing platforms.

**Report Scope and Market Segmentation**

-   **Technology:** CRISPR/Cas9, microinjections, embryonic stem cell injections, nuclear transfer, and other technologies.
-   **Application:** Drug discovery and development, research, and personalized medicine.
-   **End Use:** Pharmaceutical and biotechnology companies, academic and research institutes, CROs, and CDMOs.
-   **Geographic Coverage:** United States, Canada, Japan, China, Europe, Asia-Pacific, Latin America, the Middle East, and Africa.

**Strategic Value of the Mice Model Market Report**

-   Independent analysis of annual market value and forecasts from 2025 through 2032.
-   Evaluation of major technologies, applications, end-use markets, and geographic regions.
-   Assessment of market drivers, barriers, emerging trends, and revenue opportunities.
-   Competitive intelligence covering established providers and market participants.
-   Regional insights designed to support investment, expansion, partnership, and product development decisions.
-   Complimentary report updates for one year, providing access to relevant market developments.

**Companies Featured in the Report**

-   Charles River Laboratories International, Inc.
-   Genoway S.A.
-   Harbour BioMed
-   inGenious Targeting Laboratory, Inc.
-   Janvier Labs
-   Laboratory Corporation of America Holdings (LabCorp)
-   Revvity Discovery Limited
-   Taconic Biosciences, Inc.
-   The Jackson Laboratory
-   Trans Genic, Inc.

**Domain Expert Insights and Report Differentiators**

The analysis incorporates perspectives from domain experts across industry, enterprise, and academia, adding context beyond conventional secondary research. The report tracks early market signals emerging through expert discussions, company activity, conference sessions, keynote presentations, panel discussions, corporate disclosures, annual reports, institutional publications, and other validated sources.

These inputs are synthesized to identify the direction of the global mice model market, the forces influencing competitive change, and the developments most likely to affect corporate strategy. Company-level intelligence provides additional visibility into organizations participating in and shaping the market.

Market share is examined where it provides meaningful strategic value. Because competitive structures vary by geography, the report extends market share analysis into major regions when relevant, with the level of detail aligned to local market dynamics. This approach provides decision-makers with a more precise view of growth opportunities, competitive positioning, technology adoption, and the long-term outlook for the global mice model market.

**Key Attributes:**  
  

| Report Attribute | Details |
| --- | --- |
| No. of Pages | 385 |
| Forecast Period | 2025 - 2032 |
| Estimated Market Value (USD) in 2025 | $1.8 Billion |
| Forecasted Market Value (USD) by 2032 | $3.4 Billion |
| Compound Annual Growth Rate | 9.3% |
| Regions Covered | Global |

  
For more information about this report visit <a href="https://www.researchandmarkets.com/reports/4805185/mice-model-global-strategic-business-report-2026?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=h66mjd&amp;utm_campaign=2404484+-+Mice+Model+-+Global+Strategic+Business+Report+2026%3a+Capitalize+on+a+%243.4+Billion+Market+by+2032+as+Charles+River%2c+LabCorp%2c+Taconic+Biosciences+and+The+Jackson+Laboratory+Accelerate+CRISPR&amp;utm_exec=clshmsai" rel="nofollow">https://www.researchandmarkets.com/r/c158yl</a>

**About ResearchAndMarkets.com**  
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: 
CONTACT: ResearchAndMarkets.com 
         Laura Wood,Senior Press Manager 
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470 
         For U.S./ CAN Toll Free Call 1-800-526-8630 
         For GMT Office Hours Call +353-1-416-8900 

  
![](https://ml.globenewswire.com/media/ZGUzZjFmZmEtODU3My00ODI3LWI0ZmItZjc1YzUxN2U2MDI3LTEwMjY3MzctMjAyNi0xMS0xNi1lbg==/tiny/Research-and-Markets.png)

## Related

- [Microarray Analysis Market Size, Share, and Trends - Global Forecast 2026-2036 | Population Genotyping, Clinical Cytogenetics, and Asia-Pacific Growth Create a USD 2.58 Billion Opportunity](https://biotechnews.io/news/microarray-analysis-market-size-share-and-trends-global-forecast-2026-2036-population-geno.md)
- [Humanized Mouse and Rat Model - Global Strategic Business Report 2026: Capitalize on 9.7% CAGR to $231.6M by 2032 as Charles River, Biocytogen, Taconic and The Jackson Laboratory reshape drug R&D](https://biotechnews.io/news/humanized-mouse-and-rat-model-global-strategic-business-report-2026-capitalize-on-9-7-cagr.md)
- [In Vivo Contract Research Organization (CRO) Market - Global Forecast 2026-2032 | AI, Advanced Models, and Drug Development Outsourcing Drive 8.42% CAGR Toward USD 9.45 Billion](https://biotechnews.io/news/in-vivo-contract-research-organization-cro-market-global-forecast-2026-2032-ai-advanced-mo.md)
- [Global Full-Spectrum Fluorescence in Vivo Imaging System Market - Forecast 2026-2032 | AI-Enabled Analysis and Preclinical Research Demand Drive 8.02% CAGR Toward USD 4.14 Billion](https://biotechnews.io/news/global-full-spectrum-fluorescence-in-vivo-imaging-system-market-forecast-2026-2032-ai-enab.md)
